A recent data from Healthkoreanews showed that the average sales of 6 major domestic drug makers(Dong-A, Yuhan. LG Life Science, Green Cross, Chong Kun Dang and Hanmi) have increased 13.9 %, compared with the same period of 2008.
The principal reasons of such increase are explained as follows: the monthly sales growth of their own new drugs and the blockbuster generic drugs launched on the market in the end of last year, and the increasing demand of the drugs for adult diseases that are not so sensitive to the economy, etc.
In the first quarter of this year, Dong-A's sales are expected to increase to 173.7 billion won, up by 11.7 % compared with the same period of 2008(155.6 billion won).
Dong-A ranks first, followed by Yuhan(155.6 billion won/13%↑), Hanmi(150.1 billion won/13.1%↑), Green Cross(119.9 billion won/8%↑), Chong Kun Dang(79.7 billion won/18.4%↑), and LG Life Science(75.4 billion won/21.5%↑). <헬스코리아뉴스>
저작권자 © 헬스코리아뉴스 무단전재 및 재배포 금지